von Willebrand factor–Factor VIII complex (VWF-FVIII)

The endogenous von Willebrand factor–factor VIII (VWF-FVIII) complex is a critical circulating assembly of two distinct glycoproteins essential for blood coagulation and hemostasis [2, 7]. Von Willebrand factor (VWF) acts as a chaperone and carrier for Factor VIII (FVIII), protecting it from rapid proteolytic degradation by activated protein C and premature clearance, thereby maintaining adequate plasma levels of this essential cofactor [3, 11]. Beyond its carrier role, VWF facilitates primary hemostasis by anchoring platelets to the subendothelial matrix at sites of vascular damage via its A1 and A3 domains [10, 14]. Deficiencies or defects in either component of the complex lead to significant bleeding disorders, specifically Hemophilia A and von Willebrand disease [7, 13]. Therapeutic strategies involve the release of endogenous stores using agents like desmopressin, the administration of exogenous VWF-FVIII concentrates, or the use of novel agents that modulate the complex's stability and clearance [1, 8, 9]. Conversely, targeting the VWF component to inhibit its platelet-binding function is a strategy used in treating certain thrombotic conditions like thrombotic thrombocytopenic purpura [10, 13].

Other names

Factor VIII/von Willebrand factor complexFVIII/VWF complexAntihemophilic factor/von Willebrand factor complexEndogenous VWF-FVIII complex

The complex functions by stabilizing Factor VIII in circulation, protecting it from premature proteolytic degradation by activated protein C and extending its half-life from 1-2 hours to approximately 8-12 hours [3, 11, 22]. Additionally, the von Willebrand factor component mediates platelet adhesion to the subendothelial matrix at sites of vascular injury, facilitating the formation of a primary hemostatic plug [7, 10].